PMGC Holdings Inc. (ELAB)
ELAB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1840563/000121390026035937/0001213900-26-035937-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ELAB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001840563 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $590K |
| Net income | -$7.7M |
| Operating income | Not in SEC XBRL data |
| Net margin | -1313.0% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $5.4M |
| Total assets | $12.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $18.1M cash; operating cash flow -$2.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,168,935 (2026-11-11); 744,121 a year earlier; 17,329,615 three years earlier. 1y figure adjusted for splits (1-for-240 overall); 3y figure adjusted for splits (1-for-1178947.368 overall). | Cover page 2026-11-11 |
| Reverse splits, 3 years | 6; latest 1-for-10 on 2026-08-21 | Source 2026-08-21 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-04-20 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | HTL International, LLC, Houston, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2024-12-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $1.3M | -$2.9M | -$2.0M | $18.1M | $9.1M | $2.6M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $682K | -$5.0M | -$3.0M | $14.4M | $5.3M | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $304K | -$3.0M | -$1.8M | $5.4M | $1.3M | $590K | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | $286K | -$2.6M | -$1.5M | $7.7M | $3.2M | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$562K | -$1.3M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$1.6M | -$1.3M | $5.4M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$1.9M | -$2.0M | $4.0M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | $527K | -$1.5M | -$382K | $6.4M | $1.2M | $2.4M | 10-Q 2024-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.9% |
| 1 month | -46.6% |
| 3 months | -82.4% |
| Year to date | -99.6% |
| 1 year | -99.9% |
| From 52-week high | -99.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
| GOVX | GeoVax Labs Inc. | $2.02 | +18.48% | $1.1M |
| ENLV | Enlivex Ltd. | $1.12 | -5.88% | $1.7M |
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier